Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-02-18 Annual Report
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
GLPG FY20 financial tables.pdf
Annual Report Classification · 100% confidence The document contains detailed consolidated financial statements, including the income statement, statement of comprehensive income, statement of financial position (balance sheet), and cash flow statement for the years 2020 and 2019. It provides substantive financial data rather than just an announcement or summary. Given the comprehensive nature of these statements covering a full fiscal year, it is classified as an Annual Report (10-K). FY 2020
2021-02-18 English
GLPG 2020 financiele tabellen.pdf
Annual Report Classification · 100% confidence The document contains detailed consolidated financial statements, including the income statement, balance sheet, and cash flow statement for the fiscal year ending December 31, 2020, with comparative figures for 2019. It provides substantive financial data rather than just an announcement or summary. Given the comprehensive nature of these financial statements covering a full fiscal year, it is classified as an Annual Report (10-K). FY 2020
2021-02-18 Dutch
Pipeline and capital for growth.pdf
Earnings Release Classification · 96% confidence The document is a press release dated February 18, 2021, presenting the 'financial results 2020' and reviewing key events for the full year 2020. It contains detailed consolidated financial tables (revenues, net loss, cash position) and management commentary on performance, R&D pipeline, and outlook. This structure strongly indicates a periodic financial results announcement. Since it covers the full fiscal year (2020) and includes comprehensive financial data, it is related to the Annual Report (10-K). However, the text explicitly states: 'Galapagos expects to be able to publish its fully audited annual report for the full year 2020 on or around 25 March 2021.' Furthermore, the document announces the upcoming publication of the Annual Report and 20-F on March 25, 2021, in the financial calendar. Because this document is the preliminary announcement of the annual financial results, rather than the final, fully audited 10-K filing itself, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results (even if annual, as it precedes the formal 10-K filing). It is not the full 10-K, nor is it just a brief earnings highlight (it's quite detailed). Given the context of providing the full year's financial summary before the official 10-K publication, ER is the most appropriate classification for this pre-filing results announcement. FY 2020
2021-02-18 English
Pijplijn en groeikapitaal.pdf
Earnings Release Classification · 98% confidence The document is a press release dated February 18, 2021, announcing the financial results for the full year 2020. It contains key financial highlights (revenue, net loss, cash burn), management commentary, and detailed financial tables. The text explicitly states: 'Galapagos NV (Euronext & NASDAQ: GLPG) maakt haar financiële resultaten over 2020 bekend en geeft toelichting bij de belangrijkste gebeurtenissen voor het volledige jaar 2020.' This structure—a summary announcement of period results with key figures and commentary—is characteristic of an Earnings Release (ER). Although it discusses the upcoming Annual Report ('Jaarverslag 2020'), the document itself is the initial release of the results, not the full 10-K or the final audited report. It is too detailed for just an RPA, and it is not a transcript (CT) or a formal regulatory filing like a 10-K. FY 2020
2021-02-18 Dutch
Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
Regulatory Filings Classification · 96% confidence The document is a press release dated February 10, 2021, announcing the immediate cessation of the ISABELA Phase 3 clinical trials for the drug ziritaxestat due to an unfavorable risk-benefit profile identified by the Independent Data Monitoring Committee (IDMC). It details the decision, thanks participants, and discusses the future of related research. This type of announcement, which communicates significant, immediate corporate/clinical news outside of a standard periodic financial report (like 10-K or IR), is typically classified as an Earnings Release (ER) if it contains key financial highlights, or a Regulatory Filing (RNS) if it's a general material event disclosure. Since this is a major clinical trial termination announcement, which is material non-public information, and it is presented as a formal press release ('gereglementeerde informatie'), it fits best under the general disclosure category for material events that aren't specifically covered by other codes. While it discusses clinical results, it is not the full Audit Report (AR) or a standard Earnings Release (ER) focused on revenue/profit. Given the context of material, non-financial operational news dissemination, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although ER is sometimes used for clinical updates if they impact future earnings significantly. However, RNS covers general regulatory/material announcements not fitting elsewhere. The document length (9863 chars) is substantial, ruling out RPA/RNS based on the 'MENU VS MEAL' rule if it were merely announcing an attached report, but here the content *is* the announcement itself. I will classify this as RNS as it is a material, non-scheduled regulatory/corporate announcement.
2021-02-10 Dutch
Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
Regulatory Filings Classification · 95% confidence The document is a press release dated February 10, 2021, announcing the discontinuation of the ISABELA Phase 3 clinical trials for the drug ziritaxestat due to unfavorable benefit-risk profile recommendations from the IDMC. This type of announcement, detailing clinical trial outcomes, strategic decisions regarding drug development, and providing company updates, is characteristic of general corporate news released to the market. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a significant corporate announcement that doesn't fit the highly specific categories like M&A (TAR), Dividend (DIV), or Director Dealing (DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for important, non-standardized market communications, or potentially a Legal/Regulatory update if the trial halt was mandated, but here it is a strategic decision based on IDMC review. Given the options, RNS is the most appropriate fallback for a material press release about clinical trial status that isn't explicitly an ER or IR.
2021-02-10 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.